Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Drug pricing should depend on shared values

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Nature 552, S78 (2017)


This article is part of Nature Outlook: Cancer immunotherapy, an editorially independent supplement produced with the financial support of third parties. About this content.


  1. Rahib, L. et al. Cancer Res. 74, 2913–2921 (2014).

    Article  PubMed  CAS  Google Scholar 

  2. Institute for Clinical and Economic Review. Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks; available at:

  3. Carlson, J. J., Sullivan, S. D., Garrison, L. P., Neumann, P. J. & Veenstra, D. L. Health Policy 96, 179–190 (2010).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

S.R. is a consultant at Bayer, Genentech, BMS and Kite Pharma, and has received research grants from the Personalized Medicine Coalition.


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links